doi: 10.1161/hs0202.102326
(Stroke. 2002;33:548.)
© 2002 American Heart Association, Inc.
Original Contributions |
Apolipoprotein E Genotype and Outcome in Aneurysmal Subarachnoid Hemorrhage
From the Division of Neurosurgery, Department of Surgery (C.H.S.L., W.S.P., G.K.C.W.), and Department of Cellular and Anatomical Pathology (H.K.N.), Chinese University of Hong Kong, Prince of Wales Hospital; and Center of Clinical Trials and Epidemiological Research, Faculty of Medicine, Chinese University of Hong Kong (L.M.Y.), Shatin, Hong Kong SAR, China.
Correspondence to Dr W.S. Poon, Neurosurgical Unit, Department of Surgery, Chinese University of Hong Kong, Prince of Wales Hospital, Shatin NT, Hong Kong, China. E-mail wpoon{at}cuhk.edu.hk
Background and Purpose— Active management of ruptured intracranial aneurysm in subarachnoid hemorrhage is indicated in patients with favorable prognosis. Outcome prediction is based on patient characteristics and clinical and radiological factors. Current clinical grading scales are imprecise, with low interobserver reproducibility. Therefore, outcome prediction remains inconsistent and decision making becomes difficult, especially for patients with poor clinical grade.
Methods— The possible relationship between apolipoprotein E genotype and the outcome of patients suffering spontaneous subarachnoid hemorrhage was investigated. A prospective study was conducted on all patients with spontaneous aneurysmal subarachnoid hemorrhage admitted to our unit during a 2-year period. All patients were managed according to standard protocol, and treatments were given according to their clinical grading. Patient characteristics, clinical grade, radiological grade, and apolipoprotein E genotype were documented. The focus of the study was the 6-month neurological outcome for this group of patients after they were discharged.
Results— Seventy-two patients with aneurysmal subarachnoid hemorrhage were admitted to the Prince of Wales Hospital in Shatin, Hong Kong, China, from February 1998 to February 2000. Their ages ranged from 24 to 95 years of age, with a mean (SD) age of 58.3 (15.0) years. Apolipoprotein E 
4 was found in 15 patients (21%). At 6 months, Glasgow Outcome Scale score 
3 was found in 29 patients (40%). Univariate analysis showed that older patients (odds ratio [OR], 1.03; 95% CI, 1.00 to 1.07; P=0.07) and patients with poor Fisher’s grade (OR, 4.5; 95% CI, 1.3 to 15.2; P=0.01), poor World Federation of Neurological Surgeons grade (OR, 5.8; 95% CI, 1.9 to 17.8; P=0.002), or apolipoprotein E 4 (OR, 6.0; 95% CI, 1.7 to 21.3; P=0.006) were more likely to attain unfavorable outcome at 6 months. The additional effect of apolipoprotein E 4 remained significant in the multiple logistic regression model (OR, 11.3; 95% CI, 2.2 to 57.0; P=0.003); the gain in predictive performance was not significant (P=0.26).
Conclusions— Apolipoprotein E 4 genotype is related to poor outcome in patients with subarachnoid hemorrhage.
Key Words: apolipoproteins • outcome • subarachnoid hemorrhage
This article has been cited by other articles:
 |
|
 |
|
  L. A. Lanterna, Y. Ruigrok, S. Alexander, J. Tang, F. Biroli, L. T. Dunn, and W. S. Poon Meta-analysis of APOE genotype and subarachnoid hemorrhage: Clinical outcome and delayed ischemia Neurology, August 21, 2007; 69(8): 766 - 775. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N A Martinez-Gonzalez and C L M Sudlow Effects of apolipoprotein E genotype on outcome after ischaemic stroke, intracerebral haemorrhage and subarachnoid haemorrhage J. Neurol. Neurosurg. Psychiatry, December 1, 2006; 77(12): 1329 - 1335. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Mori, T. Town, J. Tan, N. Yada, Y. Horikoshi, J. Yamamoto, T. Shimoda, Y. Kamanaka, N. Tateishi, and T. Asano Arundic Acid Ameliorates Cerebral Amyloidosis and Gliosis in Alzheimer Transgenic Mice J. Pharmacol. Exp. Ther., August 1, 2006; 318(2): 571 - 578. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C Smith, D I Graham, L S Murray, J Stewart, and J A R Nicoll Association of APOE e4 and cerebrovascular pathology in traumatic brain injury. J. Neurol. Neurosurg. Psychiatry, March 1, 2006; 77(3): 363 - 366. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. G. Leblanc, J. F. Meschia, D. T. Stuss, and V. Hachinski Genetics of Vascular Cognitive Impairment: The Opportunity and the Challenges Stroke, January 1, 2006; 37(1): 248 - 255. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. M. Teasdale, G. D. Murray, and J. A. R. Nicoll The association between APOE {varepsilon}4, age and outcome after head injury: a prospective cohort study Brain, November 1, 2005; 128(11): 2556 - 2561. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. A. Lanterna, M. Rigoldi, G. Tredici, F. Biroli, C. Cesana, S. M. Gaini, and L. Dalpra APOE influences vasospasm and cognition of noncomatose patients with subarachnoid hemorrhage Neurology, April 12, 2005; 64(7): 1238 - 1244. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Pomara, L. Willoughby, K. Wesnes, D. J. Greenblatt, and J. J. Sidtis Apolipoprotein E {varepsilon}4 Allele and Lorazepam Effects on Memory in High-Functioning Older Adults Arch Gen Psychiatry, February 1, 2005; 62(2): 209 - 216. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W T Longstreth Jr, G D Schellenberg, C E Fahrenbruch, L A Cobb, M K Copass, and D S Siscovick Apolipoprotein E genotypes and outcome from out of hospital cardiac arrest J. Neurol. Neurosurg. Psychiatry, October 1, 2003; 74(10): 1441 - 1443. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Alberts Stroke Genetics Update Stroke, February 1, 2003; 34(2): 342 - 344. [Full Text] [PDF]
|
|